These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33030641)

  • 1. Bilateral Disease Common Among Slovenian CHEK2-Positive Breast Cancer Patients.
    Nizic-Kos T; Krajc M; Blatnik A; Stegel V; Skerl P; Novakovic S; Gazic B; Besic N
    Ann Surg Oncol; 2021 May; 28(5):2561-2570. PubMed ID: 33030641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum and frequency of CHEK2 variants in breast cancer affected and general population in the Baltic states region, initial results and literature review.
    Pavlovica K; Irmejs A; Noukas M; Palover M; Kals M; Tonisson N; Metspalu A; Gronwald J; Lubinski J; Murmane D; Kalnina A; Loza P; Maksimenko J; Trofimovics G; Subatniece S; Daneberga Z; Miklasevics E; Gardovskis J
    Eur J Med Genet; 2022 May; 65(5):104477. PubMed ID: 35314380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.
    Dettwyler SA; Thull DL; McAuliffe PF; Steiman JG; Johnson RR; Diego EJ; Mai PL
    Breast Cancer Res Treat; 2022 Jul; 194(2):393-401. PubMed ID: 35596825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
    Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
    Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Breast Cancer Risk Assessment for
    Gallagher S; Hughes E; Kurian AW; Domchek SM; Garber J; Probst B; Morris B; Tshiaba P; Meek S; Rosenthal E; Roa B; Slavin TP; Wagner S; Weitzel J; Gutin A; Lanchbury JS; Robson M
    JCO Precis Oncol; 2021 Jun; 5():. PubMed ID: 34322652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
    Rainville I; Hatcher S; Rosenthal E; Larson K; Bernhisel R; Meek S; Gorringe H; Mundt E; Manley S
    Breast Cancer Res Treat; 2020 Apr; 180(2):503-509. PubMed ID: 31993860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
    Toss A; Tenedini E; Piombino C; Venturelli M; Marchi I; Gasparini E; Barbieri E; Razzaboni E; Domati F; Caggia F; Grandi G; Combi F; Tazzioli G; Dominici M; Tagliafico E; Cortesi L
    Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
    Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
    Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
    JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational profile of hereditary breast and ovarian cancer - Establishing genetic testing guidelines in a developing country.
    Krivokuca A; Mihajlovic M; Susnjar S; Spasojevic IB; Minic I; Popovic L; Brankovic-Magic M
    Curr Probl Cancer; 2022 Feb; 46(1):100767. PubMed ID: 34284872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families.
    Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Martins A; Møller P; Hovig E
    Fam Cancer; 2018 Jan; 17(1):141-153. PubMed ID: 28608266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
    Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
    PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
    Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
    Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.
    Dettwyler SA; Koeppe ES; Jacobs MF; Stoffel EM
    Fam Cancer; 2022 Jul; 21(3):375-385. PubMed ID: 34545504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.
    Baloch AH; Daud S; Raheem N; Luqman M; Ahmad A; Rehman A; Shuja J; Rasheed S; Ali A; Kakar N; Naseeb HK; Mengal MA; Awan MA; Wasim M; Baloch DM; Ahmad J
    Mol Biol Rep; 2014 Feb; 41(2):1103-7. PubMed ID: 24390236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.
    Bychkovsky BL; Agaoglu NB; Horton C; Zhou J; Yussuf A; Hemyari P; Richardson ME; Young C; LaDuca H; McGuinness DL; Scheib R; Garber JE; Rana HQ
    JAMA Oncol; 2022 Nov; 8(11):1598-1606. PubMed ID: 36136322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers.
    Lee J; Ham JY; Park HY; Jung JH; Kim WW; Kang B; Chae YS; Lee SJ; Lee IH; Lee NY
    Sci Rep; 2022 Feb; 12(1):1842. PubMed ID: 35115620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
    Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes.
    Wei G; Teng M; Rosa M; Wang X
    Breast Cancer Res; 2022 Feb; 24(1):11. PubMed ID: 35135604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.